Synthon Holding B.V.

Synthon Holding B. V. develops, manufactures, and commercializes complex generic pharmaceuticals, primarily serving the global pharmaceutical market with a focus on oncology and innovative technologies. Founded in 1991, Synthon Holding B.

V. is based in Nijmegen, Netherlands. The company specializes in complex generics, particularly within oncology. Specific details regarding its founder and prior business ventures are not disclosed.

Synthon has established a strong presence in various international markets, including the United States, Europe, and Latin America. Synthon specializes in the development, manufacturing, and commercialization of complex generic pharmaceuticals, catering primarily to the global pharmaceutical market. The company focuses on innovative technologies and scientific rigor to create safe and effective generic medicines. Its core product offerings encompass a range of complex generics, particularly in oncology, including notable products like Abiraterone and Anastrozole.

Synthon operates in various geographical markets, including the United States and select countries across Europe and Latin America, with a robust client base primarily composed of business-to-business (B2B) partnerships. These partnerships enable Synthon to expand access to affordable medicines under the Synthon brand, ensuring that healthcare providers and patients benefit from high-quality generics. Synthon’s revenue streams are primarily derived from B2B partnerships, licensing agreements, and direct sales of its pharmaceutical products to healthcare providers and wholesalers. The company engages in exclusive licensing deals, such as its agreement with Zydus Lifesciences for Palbociclib Tablets, allowing for tailored market entry strategies in various regions, particularly the U.

S. market. Transactions typically occur in the form of supply agreements where clients order specific quantities of products based on their market demand and patient needs. Pricing structures for these products are determined through negotiation and are influenced by factors such as market conditions, regulatory considerations, and production costs.

Synthon's commitment to innovation and quality positions its flagship offerings as vital components in the treatment landscape for patients globally.